TW212184B - - Google Patents
Download PDFInfo
- Publication number
- TW212184B TW212184B TW080102180A TW80102180A TW212184B TW 212184 B TW212184 B TW 212184B TW 080102180 A TW080102180 A TW 080102180A TW 80102180 A TW80102180 A TW 80102180A TW 212184 B TW212184 B TW 212184B
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- moab
- fusion
- bispecific
- hybrid
- Prior art date
Links
- 230000002537 thrombolytic effect Effects 0.000 claims abstract description 40
- 239000003527 fibrinolytic agent Substances 0.000 claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 84
- 239000003146 anticoagulant agent Substances 0.000 claims description 40
- 238000002360 preparation method Methods 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 230000003480 fibrinolytic effect Effects 0.000 claims description 12
- 108090000190 Thrombin Proteins 0.000 claims description 11
- 229960004072 thrombin Drugs 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 108010073863 saruplase Proteins 0.000 claims description 10
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 230000009977 dual effect Effects 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 229960005356 urokinase Drugs 0.000 claims 2
- 102000016943 Muramidase Human genes 0.000 claims 1
- 108010014251 Muramidase Proteins 0.000 claims 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims 1
- 102000008212 P-Selectin Human genes 0.000 claims 1
- 108010035766 P-Selectin Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229960000274 lysozyme Drugs 0.000 claims 1
- 239000004325 lysozyme Substances 0.000 claims 1
- 235000010335 lysozyme Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 21
- 229960000103 thrombolytic agent Drugs 0.000 abstract description 12
- 230000004927 fusion Effects 0.000 description 122
- 238000000034 method Methods 0.000 description 71
- 241000699666 Mus <mouse, genus> Species 0.000 description 51
- 210000004881 tumor cell Anatomy 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 46
- 230000000694 effects Effects 0.000 description 41
- 239000000243 solution Substances 0.000 description 31
- 239000013543 active substance Substances 0.000 description 30
- 238000011049 filling Methods 0.000 description 29
- 210000002381 plasma Anatomy 0.000 description 24
- 229950003499 fibrin Drugs 0.000 description 21
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 108010073385 Fibrin Proteins 0.000 description 18
- 102000009123 Fibrin Human genes 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 230000027455 binding Effects 0.000 description 17
- 230000007910 cell fusion Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 206010003445 Ascites Diseases 0.000 description 15
- 238000009739 binding Methods 0.000 description 15
- 208000007536 Thrombosis Diseases 0.000 description 14
- 238000012216 screening Methods 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000000282 fibrinogen degradation product Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000002689 soil Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000002649 immunization Methods 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 210000000628 antibody-producing cell Anatomy 0.000 description 6
- 238000003113 dilution method Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000000284 resting effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 5
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229960003896 aminopterin Drugs 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 5
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 5
- 210000004303 peritoneum Anatomy 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 238000011891 EIA kit Methods 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000008118 PEG 6000 Substances 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 201000006491 bone marrow cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000020764 fibrinolysis Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229960003766 thrombin (human) Drugs 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- SAERAINFZWAKGQ-UHFFFAOYSA-N 2-methylbenzenesulfonyl fluoride Chemical compound CC1=CC=CC=C1S(F)(=O)=O SAERAINFZWAKGQ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010058990 Venous occlusion Diseases 0.000 description 2
- GCGKWPQZUSTFHN-UHFFFAOYSA-N [Na].[Hg].[Hg] Chemical compound [Na].[Hg].[Hg] GCGKWPQZUSTFHN-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 108010073651 fibrinmonomer Proteins 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- NPWMTBZSRRLQNJ-VKHMYHEASA-N (3s)-3-aminopiperidine-2,6-dione Chemical compound N[C@H]1CCC(=O)NC1=O NPWMTBZSRRLQNJ-VKHMYHEASA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- YTPCNCOVEFRSOV-UHFFFAOYSA-N 5-iminopyrrol-2-amine Chemical compound N=C1NC(=N)C=C1 YTPCNCOVEFRSOV-UHFFFAOYSA-N 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 101150085905 DCP2 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100035111 Farnesyl pyrophosphate synthase Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101001023007 Homo sapiens Farnesyl pyrophosphate synthase Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 101100031494 Schizosaccharomyces pombe (strain 972 / ATCC 24843) psu1 gene Proteins 0.000 description 1
- 101100422754 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sui1 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108010079337 Tissue Polypeptide Antigen Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002587 anti-hemolytic effect Effects 0.000 description 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- ISHGEXSTYZGTSI-UHFFFAOYSA-N methanesulfonic acid;hydrofluoride Chemical compound F.CS(O)(=O)=O ISHGEXSTYZGTSI-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SJXULIRYGQTEJK-UHFFFAOYSA-N n'-(2-morpholin-4-ylethyl)methanediimine Chemical compound N=C=NCCN1CCOCC1 SJXULIRYGQTEJK-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000001927 retinal artery Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8898590 | 1990-04-02 | ||
| JP17712190 | 1990-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW212184B true TW212184B (cg-RX-API-DMAC7.html) | 1993-09-01 |
Family
ID=26430304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW080102180A TW212184B (cg-RX-API-DMAC7.html) | 1990-04-02 | 1991-03-20 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5496549A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0450479B1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR910018039A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE141285T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2039259A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69121272T2 (cg-RX-API-DMAC7.html) |
| HU (1) | HUT63203A (cg-RX-API-DMAC7.html) |
| IE (1) | IE76288B1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW212184B (cg-RX-API-DMAC7.html) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001355A (en) * | 1982-12-14 | 1999-12-14 | Dowdle; Eugene Bernard Davey | Pro-tPA for the treatment of thrombosis, embolism and related conditions |
| US5620675A (en) | 1992-06-23 | 1997-04-15 | Diatech, Inc. | Radioactive peptides |
| US6017512A (en) * | 1992-06-23 | 2000-01-25 | Diatide, Inc. | Radiolabeled peptides |
| AU702250B2 (en) * | 1994-07-11 | 1999-02-18 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| US5869274A (en) * | 1995-08-09 | 1999-02-09 | Zymed Laboratories, Inc. | Immuno-histochemical method that reduces background staining |
| US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
| US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
| US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| CN1356913A (zh) | 1998-12-18 | 2002-07-03 | 杜邦药品公司 | 玻连蛋白受体拮抗剂药物 |
| US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
| US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| EP1140864A2 (en) | 1998-12-18 | 2001-10-10 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
| US7660415B2 (en) * | 2000-08-03 | 2010-02-09 | Selinfreund Richard H | Method and apparatus for controlling access to storage media |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| RU2318829C2 (ru) | 2001-11-14 | 2008-03-10 | Сентокор, Инк. | Антитела против il-6, композиции, способы и применение |
| US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
| WO2005035753A1 (ja) * | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
| EP2311945A1 (en) * | 2003-10-14 | 2011-04-20 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies substituting for functional proteins |
| EP2135619A1 (en) | 2003-12-10 | 2009-12-23 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| DK1876236T3 (da) * | 2005-04-08 | 2014-10-20 | Chugai Pharmaceutical Co Ltd | Antistof som funktionel erstatning for blodkoagulationsfaktor VIII |
| PA8672101A1 (es) | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
| EP2364998A1 (en) | 2005-06-16 | 2011-09-14 | The Feinstein Institute for Medical Research | Antibodies against HMGB1 and fragments thereof |
| HRP20130400T1 (en) | 2005-06-30 | 2013-06-30 | Janssen Biotech, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| DK2548577T3 (en) | 2005-12-29 | 2017-03-13 | Janssen Biotech Inc | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS |
| EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
| TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| RS56904B1 (sr) | 2010-03-30 | 2018-05-31 | Janssen Biotech Inc | Humanizovna il-25 antitela |
| AU2011268110B2 (en) | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
| CN103298937B (zh) | 2010-11-17 | 2016-05-25 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| WO2014144763A2 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan Kettering Cancer Center | High affinity anti-gd2 antibodies |
| JP2016527225A (ja) | 2013-07-15 | 2016-09-08 | ノヴォ ノルディスク アー／エス | ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体 |
| CN105764922B (zh) | 2013-09-27 | 2020-07-17 | 中外制药株式会社 | 多肽异源多聚体的制备方法 |
| IL301714A (en) | 2013-12-24 | 2023-05-01 | Janssen Pharmaceutica Nv | Antibodies and anti-VISTA fragments |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定ｆｖｉｉｉ的反應性之方法 |
| US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
| FI3447075T3 (fi) | 2015-05-15 | 2023-11-07 | Massachusetts Gen Hospital | Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita |
| CN114805576A (zh) | 2015-06-24 | 2022-07-29 | 詹森药业有限公司 | 抗vista抗体和片段 |
| WO2017110980A1 (ja) | 2015-12-25 | 2017-06-29 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| BR112018016461A2 (pt) | 2016-02-12 | 2019-10-01 | Janssen Pharmaceutica Nv | anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos |
| EP3436477A2 (en) | 2016-03-29 | 2019-02-06 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody |
| WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
| MX2018012648A (es) | 2016-04-28 | 2019-01-30 | Chugai Pharmaceutical Co Ltd | Preparaciones que contienen anticuerpos. |
| CA3035081A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
| ES3000618T3 (en) | 2016-09-06 | 2025-03-03 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| KR20190059305A (ko) | 2016-09-30 | 2019-05-30 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법 |
| MX2019005661A (es) | 2016-11-16 | 2019-10-07 | Janssen Biotech Inc | Método para tratar la psoriasis con el anticuerpo específico anti-il23. |
| WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| KR20240038146A (ko) | 2017-01-30 | 2024-03-22 | 얀센 바이오테크 인코포레이티드 | 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 |
| MA47442A (fr) | 2017-02-07 | 2019-12-18 | Janssen Biotech Inc | Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active |
| CN111108202B (zh) | 2017-09-29 | 2024-10-22 | 中外制药株式会社 | 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂 |
| SG11202003833TA (en) | 2017-11-01 | 2020-05-28 | Chugai Pharmaceutical Co Ltd | Antibody variant and isoform with lowered biological activity |
| MX2020004716A (es) | 2017-11-06 | 2020-11-06 | Janssen Biotech Inc | Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23. |
| MX2020009265A (es) | 2018-03-05 | 2020-10-01 | Janssen Biotech Inc | Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23. |
| JP2021523138A (ja) | 2018-05-11 | 2021-09-02 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ−２３抗体を使用してうつを治療する方法 |
| KR20210040945A (ko) | 2018-06-21 | 2021-04-14 | 유마니티 테라퓨틱스, 인크. | 신경장애의 치료 및 예방을 위한 조성물 및 방법 |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| JP7634474B2 (ja) | 2018-07-18 | 2025-02-21 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子 |
| MA55149A (fr) | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
| AU2020259982A1 (en) | 2019-04-17 | 2021-10-28 | Novo Nordisk A/S | Bispecific antibodies |
| AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
| EP3976183A1 (en) | 2019-06-03 | 2022-04-06 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
| MX2021014953A (es) | 2019-06-04 | 2022-01-24 | Janssen Biotech Inc | Metodo seguro y eficaz para tratar la artritis psoriasica con el anticuerpo especifico anti-il23. |
| WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
| JP2023524125A (ja) | 2020-05-05 | 2023-06-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ２３特異的抗体によるクローン病の治療方法 |
| CA3183927A1 (en) | 2020-05-21 | 2021-11-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| EP4178616A4 (en) | 2020-07-13 | 2024-07-24 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE METHOD FOR TREATING PSORIATIC ARTHRITIS USING A SPECIFIC ANTI-IL23 ANTIBODY |
| JP2024510588A (ja) | 2021-03-12 | 2024-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ２３特異的抗体による、ｔｎｆ療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法 |
| CA3212729A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
| CN118475608A (zh) | 2021-10-29 | 2024-08-09 | 詹森生物科技公司 | 用抗il23特异性抗体治疗克罗恩病的方法 |
| KR20240107176A (ko) | 2021-11-15 | 2024-07-08 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 크론병을 치료하는 방법 |
| IL313021A (en) | 2021-11-23 | 2024-07-01 | Janssen Biotech Inc | Method of treating ulcerative colitis with anti-il23 specific antibody |
| JP2025512860A (ja) | 2022-03-30 | 2025-04-22 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ－２３に特異的な抗体によって軽度から中等度の乾癬を治療する方法 |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| CA3257687A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | METHOD FOR EVALUATING AND TREATMENT OF PSORIATIC ARTHRITIS WITH AN IL23 ANTIBODY |
| WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
| WO2024110898A1 (en) | 2022-11-22 | 2024-05-30 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
| WO2024118866A1 (en) | 2022-12-01 | 2024-06-06 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| WO2024206126A1 (en) | 2023-03-27 | 2024-10-03 | Modernatx, Inc. | Cd16-binding antibodies and uses thereof |
| WO2025196691A1 (en) | 2024-03-20 | 2025-09-25 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4714681A (en) * | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| JP3177776B2 (ja) * | 1988-09-27 | 2001-06-18 | 武田薬品工業株式会社 | ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤 |
| CA1213229A (en) * | 1982-04-12 | 1986-10-28 | Gary S. David | Antibodies having dual specificities, their preparation and uses therefor |
| JPH0617909B2 (ja) * | 1984-04-23 | 1994-03-09 | ボストン バイオメディカル リサーチ インスティテュート，インコーポレイテッド | 双特異性抗体決定子 |
| DE3426903A1 (de) * | 1984-07-20 | 1986-01-23 | Biotest Pharma GmbH, 6000 Frankfurt | Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten |
| JP2635343B2 (ja) * | 1986-04-14 | 1997-07-30 | ザ・ジェネラル・ホスピタル・コーポレーション | ヘテロ二官能性抗体および利用方法 |
| US4889922A (en) * | 1986-08-13 | 1989-12-26 | Monsanto Co. | Monoclonal antibody specific for human colon fibroblast-derived T-PA |
| DE3909708A1 (de) * | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
-
1991
- 1991-03-20 TW TW080102180A patent/TW212184B/zh active
- 1991-03-27 AT AT91104844T patent/ATE141285T1/de not_active IP Right Cessation
- 1991-03-27 DE DE69121272T patent/DE69121272T2/de not_active Expired - Fee Related
- 1991-03-27 EP EP91104844A patent/EP0450479B1/en not_active Expired - Lifetime
- 1991-03-27 CA CA002039259A patent/CA2039259A1/en not_active Abandoned
- 1991-03-28 IE IE107991A patent/IE76288B1/en not_active IP Right Cessation
- 1991-03-28 HU HU911027A patent/HUT63203A/hu unknown
- 1991-04-02 KR KR1019910005314A patent/KR910018039A/ko not_active Ceased
-
1994
- 1994-12-06 US US08/350,497 patent/US5496549A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69121272T2 (de) | 1997-01-09 |
| KR910018039A (ko) | 1991-11-30 |
| IE76288B1 (en) | 1997-10-08 |
| IE911079A1 (en) | 1991-10-09 |
| CA2039259A1 (en) | 1991-10-03 |
| US5496549A (en) | 1996-03-05 |
| DE69121272D1 (de) | 1996-09-19 |
| EP0450479A1 (en) | 1991-10-09 |
| ATE141285T1 (de) | 1996-08-15 |
| HUT63203A (en) | 1993-07-28 |
| EP0450479B1 (en) | 1996-08-14 |
| HU911027D0 (en) | 1991-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW212184B (cg-RX-API-DMAC7.html) | ||
| JP3431140B2 (ja) | 抗体およびその使用方法 | |
| JP2837160B2 (ja) | ヒト腫瘍壊死因子に対するモノクローナル抗体を含有する敗血症治療薬及びリューマチ性疾患治療薬 | |
| JPH021552A (ja) | 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット | |
| EP0187658B1 (en) | Method and use for site-specific activation of substances | |
| JPH0616717B2 (ja) | モノクロナ−ル抗体 | |
| Bode et al. | Thrombolysis by a fibrin-specific antibody Fab′-urokinase conjugate | |
| EP0146050B1 (en) | Site selective plasminogen activator and method of making and using same | |
| Imai et al. | Lack of complement activation by human IgA immune complexes | |
| US5474766A (en) | Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator | |
| US5116613A (en) | Antibody-thrombolytic agent product and method of use | |
| JPH02500321A (ja) | ヘテロ二官能性抗体および利用方法 | |
| Schwartz et al. | Lymphocyte collaboration is required for induction of murine monocyte procoagulant activity by immune complexes. | |
| JP3177776B2 (ja) | ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤 | |
| JPH06505496A (ja) | 活性因子ｘ１１１の活性化を阻害するための組成物と方法 | |
| Podlasek et al. | Streptokinase binds to lactate dehydrogenase subunit-M, which shares an epitope with plasminogen. | |
| EP0513778A2 (en) | Hybrid monoclonal antibodies and compositions containing them | |
| WO1995029403A1 (en) | Method of assaying asialoglycoprotein receptor and assay reagent therefor | |
| JP2610808B2 (ja) | 人正常細胞由来の組織型プラスミノーゲンアクチベーターに対するモノクロナル抗体を用いる免疫学的測定試薬 | |
| JPH04218389A (ja) | 二重特異性抗体および抗体含有薬剤 | |
| US6365155B1 (en) | Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same | |
| Jeanneau et al. | Absence of functional activity of tissue plasminogen activator in patients with severe forms of von Willebrand's disease | |
| JPH04211363A (ja) | 二重特異性を有するハイブリッドモノクローナル抗体 | |
| JP2938214B2 (ja) | 血小板凝集阻害作用を持つ新規なモノクローナル抗体、およびその断片 | |
| JPH0195799A (ja) | モノクローナル抗体および免疫化学的測定方法 |